iOnctura PI3K-δ Inhibitor Patent Granted
Summary
The USPTO granted Patent US12605389B2 to iOnctura SA covering a PI3K-δ inhibitor compound and its use in methods of treating diseases where PI3Kδ pathway signaling is pathologically implicated. The patent encompasses the compound and its salts for treating cancer and inflammatory or autoimmune diseases, with 14 claims. The patent application was filed on March 29, 2022.
What changed
USPTO granted Patent US12605389B2 to iOnctura SA, covering a PI3K-δ inhibitor compound and its use in therapeutic methods. The patent specifies the compound or a pharmaceutically acceptable salt thereof for treating diseases where PI3Kδ pathway signaling is implicated, including cancer and inflammatory or autoimmune diseases. The granted patent includes 14 claims.
For competitors in the oncology and immunology space, this patent adds to the intellectual property landscape around PI3K-δ inhibitors. Pharmaceutical companies developing similar PI3K-δ targeting therapies should review their Freedom-to-Operate positions relative to this newly granted patent.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PI3K-δ inhibitor for use in treatment regimens
Grant US12605389B2 Kind: B2 Apr 21, 2026
Assignee
iOnctura SA
Inventors
Catherine Pickering, Lars Van Der Veen, Michael Lahn, Rebeca Zorrilla, Zoë Johnson
Abstract
A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.
CPC Classifications
A61K 31/5377 A61K 9/2018 A61K 9/2054 A61K 9/4858 A61K 9/4866 A61P 35/04
Filing Date
2022-03-29
Application No.
18271196
Claims
14
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.